An expert discusses the successful long-term use of amivantamab in frontline regimens like MARIPOSA, emphasizing the ...

R-DXd showed a 50.5% objective response rate in platinum-resistant ovarian cancer, with a 5.6 mg/kg dose deemed optimal for further study. The safety profile was manageable, with 93.5% experiencing ...

Patients in cohort 9 received enfortumab vedotin at 1.25 mg/kg intravenously on days 1 and 8 plus pembrolizumab at 200 mg intravenously on day 1 of each 21-day cycle. Treatment was administered until ...

Adding apalutamide (Erleada) to androgen deprivation therapy (ADT) in patients with biochemically recurrent prostate cancer reduced the risk of developing metastases and castration-resistant disease, ...

Approximately 20% to 30% of patients with NPC have recurrent or distant metastases, and current treatment options have low response rates. Iza-bren is a potentially first-in-class topoisomerase 1 ...

Tislelizumab addition to CRT improved survival in ESCC, with group B showing a 1-year PFS rate of 73% and OS rate of 85%. The trial's primary endpoint was PFS, with secondary endpoints including OS, ...

Zipalertinib showed efficacy in NSCLC with EGFR exon 20 insertions, achieving a 31.3% intracranial ORR and a 27.6% systemic ORR. The drug demonstrated a favorable safety profile, with low rates of ...

Trastuzumab rezetecan significantly improves progression-free survival in HER2-positive breast cancer, outperforming standard treatments in a pivotal trial.

The phase 3 DREAM3R study randomized patients 2:1 to receive durvalumab 1500 mg every 3 weeks plus chemotherapy every 3 weeks for 4 to 6 cycles, followed by durvalumab maintenance 1500 mg every 4 ...

212Pb-DOTAMTATE showed significant antitumor activity in PRRT-exposed GEP-NETs, with a 34.6% objective response rate and 96.2% disease control rate. The 18-month progression-free survival and overall ...

Gedatolisib combined with fulvestrant, with or without palbociclib, significantly improved PFS in HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. The triplet regimen reduced ...